Theralase Technologies Inc. (TLT.V)

0.1600 -0.0050 (-3.03%) At close: 03:43PM EDT

Theralase Technologies Inc.

41 Hollinger Road
Toronto, ON M4B 3G4
Canada
416-699-5273
https://www.theralase.com

Sector(s): Healthcare
Industry: Medical Devices
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Ms. Kristina Hachey CPA	CFO & Director	260k	N/A	N/A
Dr. Arkady Mandel DSc., M.D., Ph.D.	Chief Scientific Officer & Director	310k	N/A	N/A
Mr. Roger John Dumoulin-White B.Sc., P.Eng.	President, CEO & Director	300.8k	N/A	N/A
Mr. David M. Groves B.A	President of World Trade Division	N/A	N/A	N/A
Dr. Terry Ruch DVM	Equine Medical Consultant	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology that accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company is based in Toronto, Canada.

Corporate Governance

Theralase Technologies Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.